Aldesleukin - ILTOO Pharma

Drug Profile

Aldesleukin - ILTOO Pharma

Alternative Names: ILT-101; Low dose IL-2 - ILTOO Pharma; Low dose il2 - ILTOO Pharma; Low dose rhIL2 - ILTOO Pharma

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator Assistance Publique Hopitaux de Paris; INSERM; Universite Pierre et Marie Curie
  • Developer Assistance Publique Hopitaux de Paris; ILTOO Pharma
  • Class Antineoplastics; Interleukins; Recombinant proteins
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Systemic lupus erythematosus; Type 1 diabetes mellitus
  • Phase I Multiple sclerosis

Most Recent Events

  • 08 Aug 2016 Phase-II clinical trials in Systemic lupus erythematosus in Austria (SC) (EudraCT2016-000488-17)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Jun 2015 Phase-II clinical trials in Type-1 diabetes mellitus (Newly diagnosed) in Germany, France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top